Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
2.
Sci Rep ; 12(1): 1671, 2022 01 31.
Artículo en Inglés | MEDLINE | ID: mdl-35102253

RESUMEN

This study aimed to investigate the effect of age in patients with chronic rhinosinusitis with nasal polyp (CRSwNP). 269 patients were divided into eosinophilic and non-eosinophilic groups based on tissue eosinophilia, defined by eosinophils accounting for more than 20% of the total inflammatory cells. Patients were then further divided into younger and older groups based on the age of 35 years. Clinical characteristics including blood eosinophil, Lund Mackay score, and modified Lund-Kennedy (mLK) scores were compared. Levels of 14 cytokines from nasal tissues of an additional 78 patients were analyzed. Tissue eosinophilia was significantly associated with age and the proportion of non-eosinophilic CRSwNP was significantly higher in younger patients as compared to older patients (79.2% vs 56.6%). There was no difference in clinical characteristics and cytokine levels between the younger and older patients with eosinophilic CRSwNP. In contrast, in patients with non-eosinophilic CRSwNP, younger patients had significantly lower preoperative blood eosinophils and higher mLK scores at three and six months, postoperatively, compared to older patients. Alpha-1 antitrypsin and IL-5 levels were significantly lower in younger patients than in older patients in non-eosinophilic CRSwNP. This study suggests a potential association between age, non-type 2 inflammation and treatment outcome in CRSwNP.


Asunto(s)
Eosinofilia/cirugía , Pólipos Nasales/cirugía , Rinitis/cirugía , Sinusitis/cirugía , Adulto , Factores de Edad , Enfermedad Crónica , Estudios Transversales , Eosinofilia/diagnóstico , Eosinofilia/inmunología , Eosinofilia/metabolismo , Femenino , Humanos , Mediadores de Inflamación/metabolismo , Interleucina-5/metabolismo , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Pólipos Nasales/diagnóstico , Pólipos Nasales/inmunología , Pólipos Nasales/metabolismo , República de Corea , Estudios Retrospectivos , Rinitis/diagnóstico , Rinitis/inmunología , Rinitis/metabolismo , Sinusitis/diagnóstico , Sinusitis/inmunología , Sinusitis/metabolismo , Factores de Tiempo , Resultado del Tratamiento , alfa 1-Antitripsina/metabolismo
3.
Sci Rep ; 10(1): 4713, 2020 03 13.
Artículo en Inglés | MEDLINE | ID: mdl-32170185

RESUMEN

The effect of cell cycle synchronisation on glucose metabolism in cancer cells is not known. We assessed how cell cycle synchronisation by thiazolidinediones (TZDs) can affect glucose uptake by cancer cells and investigated the anti-cancer effect of combination therapy with TZDs and 2-deoxy-glucose (2-DG) in colon cancer cells and in mouse xenograft models. Troglitazone (58.1 ± 2.0 vs 48.6 ± 1.3%, p = 0.002) or pioglitazone (82.9 ± 1.9 vs 61.6 ± 3.4%, p < 0.001) induced cell cycle arrest in SW480 cells at G1 phase. Western blot analysis showed the degradation of cyclin D1 and CDK4, and an increase in the expression levels of p21 and p27 after TZDs treatment. Withdrawal of troglitazone treatment induced significant increase in cellular 3H-DG uptake (141.5% ± 12.9% of controls) and membrane GLUT1 expression levels (146.3% of controls) by 24 h; 1 mM 2-DG treatment alone decreased cell survival by 5.8% as compared with the controls.; however, combination therapy enhanced the anti-tumour effects to 34.6% or 20.3% as compared with control cells. In vivo, each combination treatment group showed significant anti-tumour effects unlike the 2-DG alone group. Cell cycle synchronisation using TZDs induced cellular glucose uptake, which significantly enhanced the therapeutic effect of 2-DG in colon cancer.


Asunto(s)
Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Puntos de Control del Ciclo Celular/efectos de los fármacos , Neoplasias del Colon/metabolismo , Neoplasias del Colon/patología , Desoxiglucosa/farmacología , Desoxiglucosa/uso terapéutico , Glucosa/metabolismo , Tiazolidinedionas/farmacología , Tiazolidinedionas/uso terapéutico , Animales , Puntos de Control del Ciclo Celular/genética , Neoplasias del Colon/tratamiento farmacológico , Neoplasias del Colon/genética , Ciclina D1/genética , Ciclina D1/metabolismo , Quinasa 4 Dependiente de la Ciclina/genética , Quinasa 4 Dependiente de la Ciclina/metabolismo , Sinergismo Farmacológico , Quimioterapia Combinada , Expresión Génica/efectos de los fármacos , Transportador de Glucosa de Tipo 1/genética , Transportador de Glucosa de Tipo 1/metabolismo , Humanos , Ratones , Células Tumorales Cultivadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...